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Summary In order to investigate allele loss in colorectal tumours we have developed a rapid technique which
overcomes most of the problems associated with radioactive Restriction Fragment Length Polymorphism (RFLP) analysis of allele loss. We utilise microsatellite length polymorphisms which are highly informative and are closely linked to loci of interest. Sequences containing microsatellites can be amplified from normal and tumour DNA pairs by a polymerase chain reaction (PCR) in which one of the primers is fluorescently labelled. This enables us to detect the products on polyacrylamide gels run on an automated DNA sequencer using dedicated software, by which results are automatically quantitated in terms of peak size, height, and
area.
Using this technique we have analysed 26 normal tissue: cancer pairs for allele loss at two loci linked to the adenomatous polyposis coli (APC) gene on chromosome Sq. Repeated assays yielded identical results for each pair. Allele loss was found in 10 out of 25 informative samples (40%).
The development of colorectal cancer involves a multistage
process in which a number of oncogenes and tumour sup-
pressor genes are known to play a role (for review see Fearon
& Jones, 1992). The APC gene which is located on chrom-
osome 5 region 5q21 (Kinzler et al., 1991) is known to be
involved in the sequence of events leading to colorectal
tumour development. A second gene called MCC (Mutated
in Colorectal Cancer) also maps to this chromosome region
(Kinzler et al., 1991). Deletions involving 5q have been
shown to occur in about 40% ofcolorectal tumours (Ashton-
Rickardt et al., 1989; Laurent-Puig et al., 1992).
Allele loss (Ponder, 1988) has been detected in tumours by
the use of Restriction Fragment Length Polymorphisms
(RFLP's) and more recently by the use of microsatellites.
Radioactive RFLP analysis of allele loss has many draw-
backs such as the length of time to produce results, expense
of restriction enzymes and isotopes, possible ambiguity of
results, safety aspects associated with isotope use, artefacts
due to incomplete digestion, and a high level of uninfor-
mative (homozygous) cases. Microsatellites are short tandem
repeat sequences which exhibit length polymorphisms (Ed-
wards et al., 1991; Weber et al., 1989). They occur through-
out the genome and are highly informative. Sequences based
on (dC-dA)n dinucleotide repeats have been described that
are located at, or linked to, several important gene loci, and
among these are two CA repeat stretches linked to the APC
gene (Breukel et al., 1991; van Leeuwen et al., 1991) which
we have used in this study. Sequences containing CA repeat
regions can be specifically amplified using a radioactive PCR
method, which allows the products to be detected by auto-
radiography of polyacrylamide gels. This method has yielded
results for allele loss (Futreal et al., 1992; Jones & Nakamura
1992; Louis et al., 1992). Jones & Nakamura (1992) and
Louis et al. (1992) obtained the same allele loss results using
RFLP's and CA repeats, indicating that CA repeats are a
valid alternative to RFLP's for allele loss studies. However
an intrinsic problem with dinucleotide repeats is the produc-
tion of 'stutter' bands which are thought to be caused by the
Taq polymerase in the PCR failing to read through the
repeat region thereby generating smaller fragments (Litt,
1991). These stutter bands can make autoradiographs
difficult to interpret and the bands representing the true allele
products can be difficult to identify and quantitate without
the use of a densitometer which makes loss of heterozygosity
studies arduous. Furthermore, the size of the allele products
has to be estimated in comparison to a known sequence
ladder run alongside on the gel which means that lane to lane
variation can be a problem.
The development of automated DNA sequencers which
detect fluorescent dyes has enabled us to improve the method
of detecting CA repeats for the determination of allele loss.
Microsatellite regions are amplified in a PCR in which one of
the primers is fluorescently labelled. The products are ana-
lysed by polyacrylamide gel electrophoresis in an automated
DNA sequencer which detects fluorescence emitted by the
PCR products. The results are analysed using appropriate
software which yields automatic quantitation of results in
terms ofpeak size, height and area. The quantitation ofpeak
area can then be used to calculate the change in allele ratio
between the normal and tumour DNA for each sample. In a series of colorectal tumours with matched normal
tissue we have used the APC/MCC region on chromosome
Sq as a model to assess the value of fluourescent microsatel-
lite analysis in measuring the frequency of allele loss.
Materials and methods
Samples
Fresh samples of colorectal adenocarcinomas were obtained
from 26 patients during surgery at Leeds General Infirmary from 1983 to 1987. Fresh normal colorectal tissue from the
same patients was also obtained. The tissues were snap frozen in liquid nitrogen and stored at - 80°C.
DNA extraction
Genomic DNA was extracted as described by Bell et al.
(1991). Briefly, tumour DNA was extracted from frozen sec-
tion trimmings taken adjacent to a haematoxylin and eosin
(H&E) stained section assessed for tumour content. The
tumour content in the samples used was estimated to be
50-80%. Control sections were confirmed as tumour-free
normal tissue by H&E staining before extraction. The sec-
tions were incubated for 2-3 days at 37°C with 2 mgml-'
Proteinase K (Sigma, Poole, Dorset, UK) and 1% sodium
dodecyl sulphate. This was followed by extraction twice with
phenol:chloroform:isoamyl alcohol (25:24: 1) and once with
chloroform:isoamyl alcohol (24:1). After ethanol precipita- tion at - 20°C the DNA was spun, dried, and resuspended in
distilled water. The DNA was quantitated on a TKO-100
minifluorometer (Hoefer Scientific Instruments San Fran-
cisco, California, USA) which measures the fluorescence of
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Hoescht 33258 (Polysciences Inc., Warrington, PA, USA) in
the presence of DNA.
Primers
The primer sequences used were as described by Breukel et
al. (1991) for the CA repeat proximal to APC located at the
D5S82 locus, and as described by van Leeuwen et al. (1991)
for the CA repeat at the D5S299 locus linked to APC. Both
repeats have been assigned to chromosome region 5(q15-
q23). The primers were synthesised on a Model 391 DNA
Synthesiser (Applied Biosystems, Foster City, California,
USA). One primer of each pair was coupled at the 5' end to
an aminohexyl linker (aminolink 2) using a standard DNA
synthesis cycle on the DNA synthesiser. After standard
cleavage and deprotection a fluorescent dye-NHS ester was
coupled to the oligonucleotide via this linker. The fluorescent
primer was purified successively through a NAP 10 column
(Pharmacia, Milton Keynes, UK), followed by cartridge
purification on an OPC column (Applied Biosystems, Foster
City, California, USA) and finally by thin layer chromato-
graphy (Surepure oligonucleotide purification system, United
States Biochemicals, Cleveland, Ohio, USA). The purified
fluorescent primer was eluted from the TLC plate in distilled
water and stored at - 20°C. Only one primer in each pair
was fluorescently labelled so that only one DNA strand was
detected on the gel, which made interpretation easier. Non-
fluorescent primers required no purification before use in
PCR and were stored in concentrated ammonia at - 20°C.
The ammonia was removed prior to each PCR by evapora-
tion in a vacuum desiccator.
Polymerase chain reaction
The target DNA sequences were amplified by the PCR in
25 yl of 1 x Taq polymerase reaction buffer (Promega Cor-
poration, Madison, WI, USA) containing 12.5 pmoles of
each primer (one fluorescent), 0.75 units Supertaq Taq poly-
merase (HT Biotechnology Ltd. Cambridge, UK), 1.5 mM
MgCl2, 50tLM each of dATP, dCTP, dGTP, dTTP and
25-50 ng of sample DNA. This was overlaid with mineral
oil. The DNA was amplified in a thermal cycler (Genetic
Research Instrumentation Ltd., Dunmow, Essex, UK) by one
cycle at 95°C for 5 min, 55°C for 1 min followed by an
average of 22 cycles consisting of 95°C for 30 s and 55°C for
1 min. The cycle number was optimised for each DNA sam-
ple to ensure that the PCR products were detectable but were
not over-amplified, as this caused the quantitation results for
the peaks to be inaccurate and therefore unusable. A ther-
moprobe was included in a dummy sample tube to ensure
that the samples reached the programmed cycle temperature
before the timing of the cycle began.
Polyacrylamide gel electrophoresis
PCR products were analysed on 6% polyacrylamide (Gelmix-
6, Gibco BRL, Uxbridge, Middlesex, UK) denaturing gels in
1 x TBE buffer in a Model 373A automated fluorescent
DNA sequencer (Applied Biosystems, Foster City, Califor-
nia, USA), which is a four colour detection system. One tlI of
each PCR reaction was combined with 4jil formamide and
0.5 gl of a fluorescent size marker (GS2500P, Applied Bio-
systems, Foster City, California, USA). This mix was dena-
tured for 3 min at 90°C after which 5;d was loaded into each
well on the prewarmed gel. The tumour DNA samples were
loaded 10 min after the normal samples so that any lane to
lane spillage would not affect the subsequent quantitation.
The internal size standard for each sample enables staggered
loading to be carried out. The gel was run for 4 h at 30W
and 40°C. Whilst the samples were undergoing electro-
phoresis the fluorescence detected in the laser scanning region
was collected and stored using the Genescan Collection soft-
ware (Applied Biosystems, Foster City, California, USA).
Data analysis
The fluorescent gel data collected during the run was auto-
matically analysed by the Genescan Analysis program (Ap-
plied Biosystems, Foster City, California, USA) at the end of
the run. Each fluorescent peak was quantitated in terms of
size (in base pairs), peak height and peak area.
Calculation ofallele ratios
The peaks produced by the normal DNA sample were used
to determine whether the sample was homozygous (one peak
only is seen) or heterozygous (two peaks are seen). For a
heterozygous sample the sizes of the two alleles were assigned
according to the two peaks of greatest height. The values
given for peak area of the two alleles in the paired normal
and tumour samples were used to assign a figure for allele
loss essentially as described by Solomon et al. (1987). The
ratio of alleles was calculated for each normal and tumour
sample and then the tumour ratio was divided by the normal
ratio i.e. Ti:T2/Nl:N2 where TI and Ni are the area values
of the shorter length allele product peak for the tumour and
normal sample respectively, and T2 and N2 are the area
values of the longer length allele product peak for the
tumour and normal sample respectively. In cases where the
allele ratio calculated by this equation was above 1.00 we
converted the ratio using 1/[Tl:T2/Nl:N2] to give a result
range of 0.00-1.00. At least four results were used in this
study to give a mean overall value. However, in some cases
where the tumour sample did not show allele loss and the
allele ratio was therefore around 1.00, then experimental
variation from run to run produced ratios both slightly
above and below 1.00. Thus, some ratios and means are
above 1.00.
Before beginning the study we assigned a ratio of less than
or equal to 0.50 to be indicative of loss on the basis that
tumours containing no normal contaminating cells and show-
ing complete allele loss would theoretically give a ratio of
0.00, but because some tumours in the series contained an
estimated 50% normal cells then complete allele loss in these
tumours would give an allele ratio of only 0.50.
Results
The proportion of samples which were informative (i.e.
heterozygous) with the D5S299 primers was 77% and for the
D5S82 primers this value was 69%. We found 50% of the
samples were informative with both sets of primers and only
one sample out of 26 was not informative with either primer
set. Thus information about allele loss was obtained in 96%
of cases. Non informative samples are easily determined, as
only one fluorescent peak is seen for those samples (Figure
1).
The PCR product size range observed was 158-192 and
173-181 base pairs for the D5S299 and D5S82 primer pairs
respectively as sized by the GS2500P size standard. Samples
with allele size differences of as little as two base pairs could
easily be resolved using the Genescan software.
A sample with a normal allele ratio, approaching 1.0, as
calculated from peak areas is shown in Figure 2. The relative
heights of the two alleles are similar in both the normal and
tumour sample. This can be compared with Figure 3a where
a sample with definite visual allele loss, with a ratio of 0.28,
is shown. The Genescan software enables the fluorescent
peaks from a patients normal and tumour DNA (two
separate gel lanes) to be overlaid, by changing the printout
colour for one of the lanes. This enhances the visual effect of
allele loss, as seen from Figure 3b where the normal and
tumour pair have amplified to about the same extent. How-
ever, allele loss was not always so apparent visually, espe-
cially when the normal and tumour DNA samples were not
amplified to the same extent in the PCR. This means that the
quantitated values of peak height and area are crucial for
assessing loss.
Repeated assays showed consistent values for allele ratios1264 L. CAWKWELL et al.
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2G, 3 315 180.47 1702 13864 1579
Figure 1 Electrophoretogram of a homozygous, non-informative sample. One main peak only is seen. The smaller peak is a stutter
bad. The size, height and area of the stutter band and the main peak are shown in the accompanying table.
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Figure 2 Electrophoretogram of a normal:tumour pair where no allele loss is detected. The relative peak heights of the two alleles
are very similar in the normal and tumour DNA sample and the allele ratio in this example is 0.93 (see text for calculation of allele
ratios).
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Peak/Lane Min. Size Peak Height Peak Area Scan #
IG, 13 295 172.31 182 1106 1479
2G, 13 298 174.30 1415 10220 1492
3G, 13 306 180.36 276 1921 1532
4G, 13 309 182.30 1257 9254 1545
1G, 14 315 172.46 337 2216 1578
2G, 14 318 174.44 2470 17846 1591
3G, 14 326 180.33 473 3098 1630
4G, 14 328 182.28 1994 14977 1643
I
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Lane 8: Sample 3-cancer DNA
1C
Peak/Lane Min. Size Peak Height Peak Area Scan #
1G, 7 304 172.30 161 1117 1524
2G, 7 307 174.25 1303 9969 1537
3G, 7 313 178.41 244 1841 1565
4G, 7 315 180.32 1174 8805 1578
1G, 8 327 174.44 366 2617 1635
2G, 8 332 178.37 210 1574 1661
3G, 8 334 180.33 1045 8389 1674
b
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U Lane 7: Sample 3-normal DNA U Lane 8: Sample 3-cancer DNA
Peak/Lane Min. Size Peak Height Peak Area Scan #
1G, 7 304 172.30 161 1117 1524
2G, 7 307 174.25 1303 9969 1537
3G, 7 313 178.41 244 1841 1565
4G, 7 315 180.32 1174 8805 1578
1G, 8 327 174.44 366 2617 1635
2G, 8 332 178.37 210 1574 1661
3G, 8 334 180.33 1045 8389 1674
Figure 3 a Electrophoretogram of a normal:tumour pair where allele loss is detected. An indication of loss of the smaller sized
allele in the tumour DNA can be seen by the decrease in height of this peak. The calculation of the allele ratio in this example gives
a value of 0.28 which confirms the loss. b, Stacked electrophoretograms of a sample showing allele loss. The electrophoretograms
from a, have been overlaid, with the tumour peaks now shown in magenta, to emphasise the change in height of the smaller sized
allele between the normal and the tumour DNA.
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Figure 4 Bar graph showing the range of allele ratios produced from both the D5S82 and D5S299 primers in this series. Allele
ratios given are the means of four repeat assays. Results are shown for all informative cases (13 samples were informative with both
primers). The cut off value for allele loss is 0.50 (see text for explanation of allele ratios).
of each sample (Table I). The samples which were infor-
mative with both sets of primers gave similar allele ratio
results with each primer set (Table II). We did not find gel to
gel, and PCR to PCR variation to be a problem as repeated
assays gave consistent results and at least four repeats were
carried out for each sample to ensure that our results were
accurate and consistent, and to give a mean value for the
allele ratio.
Using this method we have detected loss in the APC/MCC
region in ten out of 25 (40%) informative samples, using a
cut off value of 0.50. The range of allele ratios for the 25
Table I Allele ratio results produced using the D5S82 primers
Dukes' Standard
stage and Ist 2nd 3rd 4th error of
Sample % cancer ratio ratio ratio ratio Mean mean
1 Cl 50% 0.58 0.59 0.61 0.57 0.59 0.008
2 B 50% 0.84 0.93 0.87 0.87 0.88 0.019
3 B 60% 0.31 0.28 0.27 0.25 0.28 0.012
4 Cl 50% 0.96 0.90 0.98 0.96 0.95 0.017
S B 60% 0.45 0.46 0.45 0.44 0.45 0.004
6 B 70% 0.62 0.68 0.73 0.76 0.70 0.031
7 B 80% 0.52 0.58 0.55 0.45 0.53 0.028
8 A 50% 0.99 0.94 0.90 0.98 0.95 0.020
9 Cl 50% 0.87 0.93 0.81 0.84 0.86 0.026
10 C 70% 0.44 0.50 0.47 0.54 0.49 0.021
11 B 70% 0.00 0.16 0.13 0.13 0.11 0.036
12 B 50% 0.52 0.49 0.40 0.45 0.47 0.026
13 B 50% 0.42 0.38 0.32 0.38 0.38 0.021
14 B 50% 0.82 0.81 0.82 0.84 0.82 0.006
15 B 50% 0.70 0.98 0.86 0.98 0.88 0.066
16 B 50% 0.80 0.88 1.06 0.94 0.92 0.055
17 C2 50% 0.94 0.89 0.92 1.10 0.96 0.047
18 B 80% 1.14 0.88 0.94 1.06 1.01 0.058
Results for all informative samples with the D5S82 primers are
shown. The proportion of cancer cells in the tumour was estimated
by H&E staining.
Table II Mean allele ratio values produced using D5S82 and
D5S299 primers on the same sample
D55299 D5S82
Mean Allele Mean Allele
Sample allele ratio loss allele ratio loss
1 0.59 No 0.59 No
2 0.88 No 0.84 No
3 0.28 Yes 0.33 Yes
4 0.45 Yes 0.34 Yes
5 0.70 No 0.70 No
6 0.95 No 0.96 No
7 0.86 No 0.82 No
8 0.11 Yes 0.03 Yes
9 0.38 Yes 0.37 Yes
10 0.82 No 0.92 No
11 0.92 No 0.89 No
12 0.96 No 0.75 No
13 1.01 No 0.81 No
informative samples is shown in Figure 4. Results for both
the D5S82 and D5S299 primers are given for samples which
were informative with both primer sets. The graph appears to
show a bimodal distribution, and samples in the borderline
0.50-0.59 range could also have allele loss. Total loss of one
allele (i.e. an allele ratio of 0.00) is not usually seen because
of the normal cells which are present in most tumours.
Discussion
We have developed a rapid technique for detecting allele loss
in colorectal tumour samples which can be applied to other
tumour types and can be adapted for use with other primers
to investigate allele loss at a range of other important loci.
The results for allele loss were consistent (Table I) and the
ratios appear to form a bimodal distribution (Figure 4)
where tumours with no allele loss are separated from the
tumours which do show loss. However, a larger number of
samples needs to be assayed before this distribution can be
determined to be a significant result. The cut-off value for
loss of 0.50 appears to be consistent with the bimodal dis-
tribution, but there are borderline samples in the 0.50-0.59
range which may possibly also have allele loss. Further
studies may indicate that the cut-off value for allele loss
could be increased to 0.59 on the basis of the bimodal
distribution.
We found that the use of fluorescent technology to detect
and analyse CA repeat sequences has made it much easier to
identify and quantitate allele bands among non specific stut-
ter bands. The method described here is much more rapid
than RFLP analysis or radioactive detection of CA repeats
and the results are quantitated automatically. The through-
put is rapid as the DNA sequencer used can analyse 24 or 36
lanes simultaneously, and the use of an internal size standard
in each lane means that lane to lane variation does not affect
sizing of the PCR products. The fluorescent detection me-
thod is so sensitive that only 1 sLI of the PCR product needs
to be run on the gel therefore the cost of PCR reagents used
can be reduced by the reduction in total PCR volumes. CA
repeats are more informative than RFLPs and the use of
fluorescence as a detection method has obviated the need for
radioisotopes.
PCR as a technique is much more sensitive than Southern
blotting and requires much less DNA. Thus, DNA extracted
from minute amounts of tissue specimens can be assayed by
PCR. The added sensitivity of the fluorescent PCR technique
means that even less template DNA is required for successful
amplification. The fluorescent PCR technique is more rapid
since the enhanced sensitivity of detection requires
significantly fewer PCR cycles to achieve a detectable result.
Due to the speed of our technique (24 samples from DNA
stock to an allele loss result in 8 h) all specimens can be
assayed in four or more separate PCR reactions very quickly
to ensure that the results are reproducible. Furthermore,
since the Genescan analysis system allows four different dyeDETECTION OF ALLELE LOSS 1267
colours to be assayed simultaneously, multiplex fluorescent
PCR's are possible enabling more than one locus to be
analysed at the same time in one PCR tube (L.C. unpub-
lished results). Ifmultiplex PCR is not possible for all primer
combinations then multiple separate fluorescent PCR reac-
tion products can be loaded into a single lane for electro-
phoresis. For both multiplex PCR and multiple loading the
loci under test have to be separated either by the fluorescent
label or the size range of the products.
The technique also works well using DNA extracted from
formalin fixed, paraffin embedded material (results not
shown). This is an important factor since paraffin embedded
material is more common in historical series where follow up
data is known. In our hands the technique works well on
DNA prepared by the method described by Bell et al. (1991).
The PCR protocol is as in Materials and methods but more
PCR cycles are performed (typically 25-30).
In summary, the advantages of this allele loss detection
technique are quantitation of allele loss; accurate sizing of
PCR products; rapid generation of results as compared to
RFLP/radioactive CA repeat analyses; high sample through-
put; the possibility of assaying several markers simultaneous-
ly by multiplex PCR or multiple loading; the requirement for
very little DNA (from fresh or paraffin embedded tissue); and
the non-radioactive nature of the assay. Thus results on allele
loss can be produced rapidly, for several loci simultaneously,
for many samples. The speed and reproducibility of this
technique could enable it to be used as a diagnostic or
prognostic test in neoplasia.
This is the first description of detection of allele loss in the
APC/MCC region determined by the use of fluorescent CA
repeats. Our finding of loss in this region in 40% of colorec-
tal samples is comparable to figures given by Ashton-
Rickardt et al. (1989) and Laurent-Puig et al. (1992) using
RFLP probe techniques for 5q21-22. Any microsatellites
which are found to map within the APC gene itself would
make our assay more specific for APC loss, as small deletions
may be missed, thus underestimating the frequency of loss,
with the primers used in this study to validate the technique
of allele loss detection.
A larger series ofcolorectal cancer samples analysed in this
way, accompanied by patient survival data, will enable us to
determine whether deletions in the APC/MCC region, and
also in other regions ofthe genome, are important for patient
prognosis and this is now underway. As the range of
VNTR's and microsatellites identified that are linked to
important cancer genes increases, the development of a single
multiplexed molecular test for loss of heterozygosity in com-
mon cancers will become a distinct possibility.
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